These findings indicated that lovastatin treatment promotes DR5 expression in multiple human glioblastoma cell lines, which provides a molecular basis by which lovastatin sensitizes TRAIL-induced apoptosis in GBM. This evidence concerns the gene TNFSF10 and glioblastoma.